TargetMol

VAS 3947

Product Code:
 
TAR-T29097
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29097-1mg1mg£138.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29097-5mg5mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29097-1mL1 mL * 10 mM (in DMSO)£252.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29097-10mg10mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29097-25mg25mg£576.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29097-50mg50mg£790.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29097-100mg100mg£1,050.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29097-500mg500mg£2,038.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
VAS3947 is a selective inhibitor of NADPH oxidase activity.
CAS:
869853-70-3
Formula:
C14H10N6OS
Molecular Weight:
310.34
Pathway:
Apoptosis|Immunology/Inflammation
Purity:
0.98
SMILES:
C(c1ccccc1)n1nnc2c(Sc3ncco3)ncnc12
Target:
Apoptosis|NADPH-oxidase

References

1. Hecht N, Terveer N, Schollmayer C, Holzgrabe U, Meinel L. Opening NADPH oxidase inhibitors for in vivo translation. Eur J Pharm Biopharm. 2017 Jun;115:206-217. doi: 10.1016/j.ejpb.2017.03.001. Epub 2017 Mar 8. PubMed PMID: 28284727. 2. Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol. 2012 May-Jun;56(5-6):216-31. doi: 10.1016/j.vph.2012.02.012. Epub 2012 Mar 3. Review. PubMed PMID: 22405985; PubMed Central PMCID: PMC3378316. 3. Wind S, Beuerlein K, Eucker T, M?ller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010 Oct;161(4):885-98. doi: 10.1111/j.1476-5381.2010.00920.x. PubMed PMID: 20860666; PubMed Central PMCID: PMC2970907.